Department of Cardiology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Department of Cardiology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Heart Rhythm. 2022 Sep;19(9):1541-1547. doi: 10.1016/j.hrthm.2022.05.008. Epub 2022 May 12.
Cardiac arrhythmia is a common cardiovascular disease that leads to considerable economic burdens and significant global public health challenges. Despite the remarkable progress made in recent decades, antiarrhythmic therapy remains suboptimal. Aldehyde dehydrogenase 2 (ALDH2), a critical detoxifying enzyme, catalyzes toxic aldehydes and protects individuals from damage caused by oxidative stress. Accumulating evidence has demonstrated that ALDH2 activation has potential antiarrhythmic benefits. The correlation between ALDH2 deficiency and arrhythmogenesis has been widely recognized. In this review, we summarize recent research on the potential role of ALDH2 activation and antiarrhythmic protection, as well as the role played by the ALDH2∗2 polymorphism (rs671) in promoting arrhythmic risk. Additionally, we discuss important new findings illustrating the use of ALDH2 activators, which may prove to be promising antiarrhythmic therapy agents.
心律失常是一种常见的心血管疾病，会导致相当大的经济负担和重大的全球公共卫生挑战。尽管在最近几十年取得了显著进展，但抗心律失常治疗仍然不尽如人意。醛脱氢酶 2（ALDH2）是一种关键的解毒酶，可催化有毒醛类物质，保护个体免受氧化应激造成的损伤。越来越多的证据表明，ALDH2 的激活具有潜在的抗心律失常益处。ALDH2 缺乏与心律失常发生之间的相关性已得到广泛认可。在这篇综述中，我们总结了最近关于 ALDH2 激活和抗心律失常保护作用的研究，以及 ALDH2∗2 多态性（rs671）在促进心律失常风险方面的作用。此外，我们还讨论了一些重要的新发现，这些发现表明使用 ALDH2 激活剂可能是一种有前途的抗心律失常治疗药物。
